CSPC Pharmaceutical Group (01093.HK): Receives US$30 Million Upfront Payment Under siRNA Collaboration Agreement with AstraZeneca
NewTimeSpace News: On 12 August 2026, CSPC Pharmaceutical Group (01093.HK) announced that under the strategic research and development collaboration agreement signed with AstraZeneca in July 2026, the Group has received the US$30 million upfront payment from AstraZeneca on 12 August 2026.
CSPC Pharmaceutical Group said the collaboration intends to utilise the Group’s proprietary siRNA drug discovery platform and extrahepatic targeted delivery platform to develop novel small nucleic acid drug candidates.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CSPC Pharmaceutical Group (01093.HK): Phase I Clinical Trial of SYS6063 for Relapsed and Refractory Systemic Lupus Erythematosus Initiated at First Study Site in China
- CSPC Pharmaceutical Group (01093.HK): Monkeypox mRNA Vaccine SYS6037 Granted US FDA Clinical Trial Approval
- CSPC Pharmaceutical Group (01093.HK): Phase II Clinical Trial of Albumin-bound Sirolimus for Injection Officially Launched
- CSPC Pharmaceutical Group (01093.HK): Albumin-Bound Docetaxel Combined with Anitumab Granted Breakthrough Therapy Designation
- CSPC Pharmaceutical Group (01093.HK): Phase III Clinical Trial of SYS6010 Combined with Enlimomab as Adjuvant Therapy for NSCLC Officially Launched
